Diabetes drug shows promise in fighting advanced cancers
NCT ID NCT07703163
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial investigates whether canagliflozin, a diabetes drug, can be safely combined with the immunotherapy tislelizumab to treat advanced solid tumors. The study includes adults with unresectable, recurrent, or metastatic cancers who have not responded to standard treatments. Researchers will monitor side effects and measure how long patients live without their cancer worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- canagliflozin combined with tislelizumab
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors by combining metabolic and immune therapy.
- What could go wrong
- This is an early-phase trial with only 15 participants, so results may not apply broadly. Side effects from the combination are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?